Patent ID: 9023377
Filing Date: 2015-05-05
Classification: A61L,C12N

Abstract:
1. An implantable material prepared by a method comprising the steps of: cryopreserving at −4° C. to −160° C. for at least 1 month a population of vascular endothelial cells having an inhibitory phenotype such that they are capable of inhibiting or interfering with vascular smooth muscle cell proliferation, said cells attached via cell to matrix interactions to a flexible planar or flowable biocompatible substrate, wherein said inhibitory phenotype is selected from the group consisting of: expression of heparin sulfate of at least 200 ng/mL/day, expression of TGF-beta of at least 300 pg/mL/day, and expression of b-FGF of no more than 300 pg/mL/day; and wherein said population of cells is at least 80% viable prior to and following cryopreservation; and thawing said cryopreserved implantable material in a transport media composition comprising EGM-2 supplemented with an amount of VEGF sufficient to maintain both cell viability and said inhibitory phenotype for an extended period of time when said implantable material is stored at temperatures below the cells' standard cell culture temperature.